Abstract
Core Needle Biopsy (CNB) has been widely used as a diagnostic tool for breast tumors. However, this technique involves tissue sampling as opposed to complete surgical lesion excision, introducing the possibility of underestimation of disease. The purpose of this study was to assess the reliability of CNB in breast tumors. This was a retrospective cross-sectional study from January 2023 to July 2023. All included patients underwent Core Needle Biopsy (CNB) and subsequent Surgical Excision (SE) of a breast tumor. One hundred fifty patients were assessed. All patients were female. The median age for malignancies was 45 years and 31 years for benign tumors. Concordance regarding the tumor type was globally moderate (k= 0.67; p<0,001) with a rate of 97.6% for CNB-diagnosed malignant tumors and 62.5% for CNB-diagnosed benign tumors. Concordance for histological types was perfect for CNB-diagnosed ILC (rate= 100%; k= 1; p<0,001) and almost perfect for IDC (rate= 96.7%; k= 0.94; p<0,001). The concordance between Core Needle Biopsy (CNB) and surgical excision specimen in the diagnosis of malignancy and benignity of breast tumors is almost perfect for CNB-diagnosed malignancies and moderate for benign tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.